Brain-targeted solid lipid nanoparticles containing riluzole: Preparation, characterization and biodistribution

Nanomedicine

Volumn 5, Issue 1, 2010, Pages 25-32

  Bondì, Maria Luisa ^a   Craparo, Emanuela Fabiola ^b   Giammona, Gaetano ^b,c   Drago, Filippo ^d  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Biodistribution; Modified release; Nanoparticles; Riluzole; Solid lipid

Indexed keywords

GLYCEROL BEHENATE; RILUZOLE; SOLID LIPID NANOPARTICLE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; CENTRAL NERVOUS SYSTEM; COLLOID; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISCRIMINATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; MALE; MICROEMULSION; MULTIPLE SCLEROSIS; NERVE CELL LESION; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; DRUG CARRIERS; DRUG STABILITY; HUMANS; LIPIDS; MALE; NANOPARTICLES; NEUROPROTECTIVE AGENTS; PARTICLE SIZE; PLASMA; RATS; RATS, SPRAGUE-DAWLEY; RILUZOLE;

EID: 75949119718     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.67     Document Type: Article

References (18)

1. Mehnert W, Mader K: Solid lipid nanoparticles. Production, characterization and applications. Adv. Drug Deliv. Rev. 47(2-3), 165-196 (2001).
2. Wissing SA, Kayser O, Muller RH: Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56(9), 1257-1272 (2004).
3. Montana G, Bondì ML, Carrotta R et al.: Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjugate Chem. 18(2), 302-307 (2007).
4. Chen D, Yang T, Liang W et al.: In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 49(11), 1444-1447 (2001).
5. Reddy JS, Venkateswarlu V: Novel delivery systems for drug targeting to the brain. Drugs Future 29(1), 63-83 (2004).
6. Yang S, Zhu J, Lu Y et al.: Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 16(5), 751-757 (1999).
7. Kreuter J: Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47(1), 65-81 (2001). • Describes the supposed mechanisms of nanoparticle-mediated drug transport to the brain.
8. Kaur IP, Bhandari R, Bhandari S et al.: Potential of solid lipid nanoparticles in brain targeting. J. Control. Rel. 127(2), 97-109 (2008). •• Describes the potential of solid lipid nanoparticles in brain targeting.
9. Joshi MD, Müller RH: Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71(2), 161-172 (2009). • Describes the potential of solid lipid nanoparticles in brain targeting.
10. Miller RG, Mitchell JD, Lyon M et al.: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 1, CD001447 (2007). •• Demonstrates the clinical utility of riluzole in patients with amyotrophic lateral sclerosis.
11. Storch A, Burkhardt K, Ludolph AC et al.: Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J. Neurochem. 75(6), 2259-2269 (2000).
12. Louhimies S: Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes. Altern. Lab. Anim. 30(Suppl. 2), 217-219 (2002).
13. Issazadeh S, Lorentzen JC, Mustafa MI et al.: Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β. J. Neuroimmunol. 69(1-2), 103-115 (1996).
14. Bondì ML, Craparo EF, Giammona G et al.: Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv. 14(2), 61-67 (2007).
15. Lockman PR, Koziara J, Roder KE et al.: In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 20(5), 705-713 (2003).
16. Kerlero de Rosbo N, Mendel I, Ben-Nun A: Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PLJ mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary ana lysis of MOG T cell epitopes. Eur. J. Immunol. 25(4), 985-993 (1995). •• Supports the theory that experimental allergic encephalomyelitis does not induce changes in blood-brain barrier permeability for up to 7 days.
17. Muller RH, Lucks JS: EP-0605497 (1996).
18. Bondì ML, Craparo EF, Giammona G, Drago F: WO2008/000448 A2 (2008).